U.S. Aerospace & Defense Stock News

If you are wondering whether Agnico Eagle Mines is still good value after its huge run, you are not alone. This is exactly the question we will unpack. The stock has climbed to around $168.61, delivering an impressive 105.6% year to date and 118.5% over the last year, on top of substantial multi year gains of 243.3% over 3 years and 167.4% over 5 years. Recent market attention has centered on gold prices holding firm near multi year highs and ongoing geopolitical uncertainty, both of which...

Pentair plc ( NYSE:PNR ) has announced that it will be increasing its dividend from last year's comparable payment on...

Key Insights Mega Fortune's estimated fair value is US$9.33 based on 2 Stage Free Cash Flow to Equity With US$8.78...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

The Manitowoc Company, Inc. ( NYSE:MTW ) shares have continued their recent momentum with a 25% gain in the last month...

DXC Technology Company ( NYSE:DXC ) shareholders would be excited to see that the share price has had a great month...

The Estée Lauder Companies Inc. ( NYSE:EL ) shareholders have had their patience rewarded with a 26% share price jump...

Quad/Graphics, Inc. ( NYSE:QUAD ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...

FMC Corporation ( NYSE:FMC ) is reducing its dividend from last year's comparable payment to $0.08 on the 15th of...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

eHealth, Inc. ( NASDAQ:EHTH ) shareholders would be excited to see that the share price has had a great month, posting...

Monte Rosa Therapeutics (GLUE) just gave investors a fresh catalyst, sharing interim Phase 1/2 data showing 100% disease control and PSA responses in a key prostate cancer subgroup, along with plans for a follow up Phase 2 trial. See our latest analysis for Monte Rosa Therapeutics. That strength in the clinic has gone hand in hand with shifting sentiment in the stock, with a 150.08% 3 month share price return and 128.43% 1 year total shareholder return signaling powerful, still building...

Earlier this quarter, Belden reported record third-quarter revenue and adjusted earnings per share, beating analyst expectations and delivering stronger-than-anticipated operating income and Enterprise segment performance. Riverwater Partners’ latest Small Cap Strategy letter emphasized CEO Dr. Ashish Chand’s solutions-focused networking approach and Horizon software platform as key drivers of Belden’s consistent high single-digit revenue growth and double-digit adjusted EPS gains,...

Workday (WDAY) is back in the spotlight after unveiling fresh partnerships that deepen its compensation and AI agent ecosystem, moves that matter less for today’s share price and more for its long term platform stickiness. See our latest analysis for Workday. That backdrop of new partnerships lands at a tricky moment for sentiment, with the share price at $218.08 after a soft recent stretch, including a negative year to date share price return and a weaker 1 year total shareholder return,...

Earlier this week, reports that the House Speaker would not allow a vote on renewing Affordable Care Act premium subsidies raised fresh concerns about Centene’s ACA marketplace exposure and the broader pressure of rising medical costs on health insurers’ profitability. At the same time, Centene’s Ambetter Health and Sunshine Health units have been rolling out community-focused partnerships with professional and elite athletes, highlighting the company’s emphasis on preventive care, Medicaid...

Virtu Financial (VIRT) has quietly lagged the market this year, even though its longer term returns remain strong. That gap between recent weakness and multi year strength is what makes the stock interesting now. See our latest analysis for Virtu Financial. Over the past year, Virtu’s modest 1 year total shareholder return decline contrasts with its strong three and five year total shareholder returns. This suggests momentum has cooled lately even as the long term story still looks intact at...

Rapport Therapeutics recently reported new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, presented at the 2025 American Epilepsy Society Meeting, highlighting statistically significant improvements in several seizure-related patient-reported outcomes and confirming target engagement in key brain regions. The company also outlined plans for an end-of-Phase 2 meeting with the FDA and the potential launch of two pivotal Phase 3 trials in...

Earlier in December 2025, Ocular Therapeutix said it now plans to file a New Drug Application for its wet AMD candidate AXPAXLI (OTX-TKI) based on positive year-one data from the ongoing SOL-1 Phase 3 trial, with those data expected in the first quarter of 2026. This shift reflects recent feedback and public comments from the FDA that could allow AXPAXLI to pursue approval using a single pivotal trial and the 505(b)(2) pathway, potentially shortening the route to market if results support...

Strategic moves reshape the outlook for Noble stock Noble (NE) just set a new course by agreeing to sell six jackup rigs, doubling down on deepwater and ultra harsh environments, while its Globetrotter I drillship reaches the Black Sea and a major bank issues a downgrade. See our latest analysis for Noble. Those portfolio moves and the downgrade are landing against a weak backdrop, with the share price down sharply on a year to date basis. Yet a modestly positive 1 year total shareholder...

Earlier in December 2025, Atai Life Sciences N.V. received a new U.S. patent for EMP-01, its oral R-MDMA formulation being developed for social anxiety disorder and other mental health indications, providing exclusivity through 2043. This long-dated patent protection strengthens Atai’s intellectual property position around EMP-01 just as an exploratory Phase 2a trial is enrolling, with topline results expected in the first quarter of 2026. We’ll now examine how this extended patent...

Zai Lab Limited recently dosed the first participant in a global randomized, double-blind, placebo-controlled Phase 1/1b trial of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for moderate-to-severe atopic dermatitis, following encouraging preclinical data presented at the 2025 EAACI Congress. The internally discovered ZL-1503, designed to suppress both inflammatory and itch-related pathways with an extended half-life, could meaningfully broaden Zai Lab’s immunology...

Iron Mountain (IRM) has quietly pulled back, with the stock down around 21% over the past 3 months and roughly 25% year to date. This has raised fresh questions about whether this long term winner is finally on sale. See our latest analysis for Iron Mountain. At around $78.86, Iron Mountain’s recent slide, including a sharp 7 day share price return of negative 10.42 percent and a 1 year total shareholder return of negative 19.6 percent, suggests momentum is fading in the short term even...

Solventum (SOLV) just picked up a meaningful endorsement, with new international clinical guidance expanding how its Prevena closed incision negative pressure therapy can be used across surgeries that prioritize patient safety. See our latest analysis for Solventum. These endorsements and the recent Acera Surgical deal have arrived against a constructive backdrop, with Solventum’s 90 day share price return of 9.44 percent and year to date share price return of 22.37 percent hinting that...

On 11 December 2025, Byline Bancorp, Inc. announced that its board had authorized a share repurchase program for up to 2,250,000 shares, or 4.9% of its outstanding stock, running through 31 December 2026, with repurchased shares available for equity incentive plans and other corporate uses. This buyback authorization signals management’s willingness to use excess capital to adjust the share count and potentially influence future capital allocation flexibility. We’ll now examine how this...